WARRINGTON, Pa., Aug. 13, 2020 (GLOBE NEWSWIRE) — Windtree Therapeutics, Inc. (NASDAQ: WINT), a biotechnology and medical device company focused on developing drug product candidates and medical device technologies to address acute cardiovascular and pulmonary diseases, today reported financial results for the second quarter ended June 30, 2020 and provided […]
Other News
Hyperfine Research Receives 510(k) Clearance from US FDA for Market-Ready Swoop™ Portable MRI System
Novel technology defines new product category for accessible, cost-effective point-of-care magnetic resonance imaging. GUILFORD, Conn.–(BUSINESS WIRE)–Hyperfine Research, Inc. has received 510(k) clearance from the US FDA for its category-defining portable MRI technology, the Swoop™ Portable MR imaging device. Hyperfine’s Swoop™ system is a point-of-care MR imaging device that wheels directly to […]
Neovasc Provides Corporate Update
VANCOUVER and MINNEAPOLIS, MN, Aug. 13, 2020 (GLOBE NEWSWIRE) — via NEWMEDIAWIRE — Neovasc, Inc. (“Neovasc” or the “Company”) (NASDAQ, TSX: NVCN), today provided a corporate update on progress towards its value creation strategies. Fred Colen, Chief Executive Officer of Neovasc, commented, “We are pleased to provide a corporate update to our investors as we have […]
BioCardia Reports Second Quarter 2020 Financial Results and Business Highlights
SAN CARLOS, Calif., Aug. 13, 2020 (GLOBE NEWSWIRE) — BioCardia®, Inc. [NASDAQ: BCDA], a leader in the development of comprehensive solutions for cardiovascular regenerative therapies, today reported financial results and business highlights for the second quarter of 2020 and filed its quarterly report on Form 10-Q for the three and six months […]
Caladrius Biosciences Provides Corporate Update and Reports 2020 Second Quarter Financial Results
Clinical programs advanced and expanded with strengthened cash position Conference call begins today at 4:30 p.m. Eastern time BASKING RIDGE, N.J., Aug. 13, 2020 (GLOBE NEWSWIRE) — Caladrius Biosciences, Inc. (Nasdaq: CLBS) (“Caladrius” or the “Company”), a clinical-stage biopharmaceutical company dedicated to the development of cellular therapies designed to reverse, not […]
Acasti Pharma Provides Business Update for the First Quarter of Fiscal 2021
On track to report TRILOGY 2 topline data on or about August 31, 2020 LAVAL, Québec, Aug. 13, 2020 (GLOBE NEWSWIRE) — Acasti Pharma Inc. (“Acasti or the “Company”) (NASDAQ: ACST – TSX-V: ACST), a biopharmaceutical innovator focused on the research, development and commercialization of its prescription drug candidate CaPre® […]
CE Marking Received for Core European Product, DyeVert Power XT
Key Highlights Osprey Medical has received European CE Marking approval for the 2nd generation DyeVert Power XT device Approval of DyeVert Power XT (for automatic injection) means the full coronary angiography market is now available to Osprey’s DyeVert franchise Device is expected to be a core product in the product portfolio […]
CORRECTING and REPLACING FDA Approves Gadavist® (gadobutrol) Imaging Bulk Package
The first and only FDA-approved gadolinium-based contrast agent for multi-patient dosing with an FDA-cleared Transfer Spike in the MR suite. INDIANOLA, Pa.–(BUSINESS WIRE)–Please replace the release with the following corrected version due to multiple revisions. The updated release reads: FDA APPROVES GADAVIST® (GADOBUTROL) IMAGING BULK PACKAGE The first and only FDA-approved […]
scPharmaceuticals Inc. Reports Second Quarter 2020 Financial Results and Provides Business Update
Preparations ongoing for December 30, 2020 FUROSCIX® PDUFA date BURLINGTON, Mass.–(BUSINESS WIRE)–scPharmaceuticals Inc. (Nasdaq: SCPH), a pharmaceutical company focused on developing and commercializing products that have the potential to optimize the delivery of infused therapies, advance patient care, and reduce healthcare costs, today announced financial results for the second quarter ended […]
LivaNova to Present Autonomic Regulation Therapy Findings for Heart Failure During European Society of Cardiology Congress 2020
LONDON–(BUSINESS WIRE)–LivaNova PLC (NASDAQ:LIVN) a market-leading medical technology and innovation company, today announced it will present a poster at the European Society of Cardiology (ESC) Congress 2020 on the potential for autonomic regulation therapy (ART) via vagus nerve stimulation to improve long-term cardiovascular function in patients with heart failure. The virtual Congress […]
